Background: Botulinum toxin (BoNT) type A, commonly known by its brand name Botox, has gained widespread recognition as a therapeutic intervention for conditions such as blepharospasm and hemifacial spasm. These conditions are classified as focal dystonias and are characterized by involuntary muscle contractions that can cause both functional disabilities and cosmetic concerns for those affected. Objective: The primary aim of this study was to comprehensively assess the efficacy, safety, and tolerability profile of Botulinum toxin in a cohort of 21 patients, comprised of 16 individuals diagnosed with blepharospasm and 5 with hemifacial spasm. Methods: Each patient underwent a series of Botox injections tailored to their specific condition and symptom severity. Following the administration of the treatment, participants were closely monitored over a six-month period to evaluate clinical outcomes and any potential adverse effects. Results: The treatment with Botulinum toxin resulted in a significant reduction in the frequency and intensity of involuntary muscle contractions in all participants. Furthermore, patients reported substantial improvements in their quality of life, indicating enhanced daily functioning and overall well-being. Notably, the treatment was generally well-tolerated, with only a few mild side effects, suggesting that adverse reactions were minimal and manageable. Conclusion: The findings from this study bolster the evidence supporting the use of Botulinum toxin as an effective first-line treatment option for individuals suffering from both blepharospasm and hemifacial spasm. The promising results highlight its role in alleviating symptoms and improving the quality of life for patients affected by these challenging conditions.
Key words: botulinum toxin, BoNT, blepharospasm, hemifacial spasm.
|
